Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia, DF, Brazil; Cell Biology Department, University of Brasilia, Brasilia, DF, Brazil; Jose Alencar Children's Hospital of Brasilia, Brasilia, DF, Brazil.
Laboratory of Genomic Sciences and Molecular Biotechnology, Catholic University of Brasilia, Brasilia, DF, Brazil.
Leuk Res. 2014 Apr;38(4):496-502. doi: 10.1016/j.leukres.2014.01.013. Epub 2014 Feb 5.
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. In this study, we performed quantitative real time PCR to compare the expression of SMYD2 in 83 pediatric ALL patients and non-neoplastic bone marrow samples (BMS). The study revealed that SMYD2 expression is altered in ALL BMS and its high expression was correlated with a bad prognosis. Moreover, we also revealed that SMYD2 expression level significantly decreases in patients that respond to chemotherapy treatment.
急性淋巴细胞白血病（ALL）是最常见的儿童恶性肿瘤。尽管有几种临床特征与预后不良相关，但仍未发现更可靠的生物学标志物。SMYD2 是 SMYD 蛋白家族的成员，通过甲基化调节几种蛋白质的活性。在这项研究中，我们通过定量实时 PCR 比较了 83 例儿科 ALL 患者和非肿瘤性骨髓样本（BMS）中 SMYD2 的表达。研究表明，SMYD2 在 ALL BMS 中的表达发生改变，其高表达与预后不良相关。此外，我们还发现，对化疗有反应的患者中 SMYD2 的表达水平显著降低。
Zotero 插件